Rippl Plans Next Chapter of Growth After New $23M Fundraise

Behavioral health and virtual dementia care platform Rippl continues to scale its operations, most recently with a $23 million fundraise. Seattle, Washington-based Rippl raised the funds in Series A capital to expand services to new states and create value-based care partnerships with payors and payviders to expand dementia care offerings. The latest fundraising was led […]

Where Older Adults Live May Influence Their Chance of Being Diagnosed With Alzheimer’s

An older adult’s chance of getting a diagnosis of Alzheimer’s or another form of dementia may depend on where they live. That’s according to a new study conducted by researchers at the University of Michigan and Dartmouth College and published in the journal “Alzheimer’s & Dementia.” The study’s researchers examined Medicare claims from 4.8 million […]

Mississippi, Alabama, Washington Have Highest Alzheimer’s Death Rates

Mississippi, Alabama and Washington are the top three states with the highest death rates for people living with Alzheimer’s disease. That’s according to U.S. News & World Report, which combed through publicly available data from the U.S. Centers for Disease Control and Prevention (CDC) that tracked the causes of death among people in 2022. Alzheimer’s, […]

Memory Care Sector Needs 1 Million More Direct Care Workers by 2031

The memory care sector requires one million new direct care workers by 2031, a need greater than in any other occupation in the U.S. That’s according to the latest Alzheimer’s Association 2024 Facts and Findings report, released earlier this month. The annual report details national and state statistics related to Alzheimer’s prevalence, mortality, cost of […]

New Definition of Alzheimer’s Would Expand Diagnosis to People Without Memory Problems

A debate has simmered in the world of Alzheimer’s research and treatment: Should the disease’s definition be expanded to older adults who have a higher risk of dementia, but currently lack memory problems? The answer to that question, at least according to certain researchers, is yes. As noted in a recent Los Angeles Times article, […]

Alzheimer’s Association Gets $25M Grant to Improve Respite Support for Dementia Caregivers

The Alzheimer’s Association says it will use a new $25 million grant to provide more resources, and support to give more respite breaks to caregivers of people living with dementia. The grant is creating a new  Center for Dementia Respite Innovation (CDRI) to “fund new respite care innovation projects across the country,” including for friends or […]

UC-Davis, Northwestern Researchers Link Certain Personality Traits to Dementia Risk 

A recent article published in the Journal of the Alzheimer’s Association could give insights into just how personality traits impact a person’s likelihood to be diagnosed with dementia. The research, conducted by the University of California Davis and Northwestern University, posits that people with personality traits including positive affect, extraversion and conscientiousness are less likely […]

Why Alzheimer’s Could Be Near Its ‘Magic Johnson Moment’ in Becoming Manageable Condition

When basketball legend Magic Johnson announced in 1991 that he had been diagnosed with HIV, the news carried the weight of a nearly certain death sentence. But of course, Johnson would be fortunate enough to survive until the advent of effective treatments, and he is living a full life three decades after his diagnosis. It’s […]

Inside the Treatments, Tech and Tools Pushing Memory Care Into the Future

By Sloane Airey The future of memory care lies in technology, treatments and training. As the incoming baby boomer generation looms large over the industry, memory care operators and experts are in 2023 employing tools that include AI-powered tech, new Alzheimer’s-fighting drugs, and tried-and-true methods to move the sector forward for residents across the country. […]

Not As Good As We Think: Memory Care Providers See Risks in Newly Approved Alzheimer’s Drug

In early June, the Food and Drug Administration (FDA) approved the use of Aduhelm (aducanumab) to treat patients with Alzheimer’s disease — the first drug therapy in 18 years to receive approval. The approval is surrounded in controversy, however. In particular, much reporting on Aduhelm has centered on its cost and concerns about its efficacy […]